ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-11 pm EDT 5-day change 1st Jan Change
11.11 USD +6.21% Intraday chart for ARS Pharmaceuticals, Inc. +22.22% +102.74%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing MT
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing MT
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000E Value Index CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Value Index CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000 Value Index CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2500 Value Index CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Microcap Value Index CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index CI
ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion MT
EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen RE
ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis) CI
Ars Pharmaceuticals Insider Sold Shares Worth $913,917, According to a Recent SEC Filing MT
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp CI
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand CI
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing MT
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy MT
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy DJ
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray) CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index CI
North American Morning Briefing : Stock Futures -2- DJ
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6 MT
Chart ARS Pharmaceuticals, Inc.
More charts
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.11 USD
Average target price
19 USD
Spread / Average Target
+71.02%
Consensus
  1. Stock Market
  2. Equities
  3. SPRY Stock
  4. News ARS Pharmaceuticals, Inc.
  5. ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing